Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: The growth rate constant as an indicator of therapeutic efficacy

Clinical Cancer Research

Volumn 17, Issue 4, 2011, Pages 907-917

  Stein, Wilfred D ^a,b   Gulley, James L ^a   Schlom, Jeff ^a   Madan, Ravi A ^a   Dahut, William ^a   Figg, William D ^a   Ning, Yang Min ^c   Arlen, Phil M ^a   Price, Doug ^a   Bates, Susan E ^a   Fojo, Tito ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BEVACIZUMAB; DOCETAXEL; HEMOGLOBIN; KETOCONAZOLE; LACTATE DEHYDROGENASE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; THALIDOMIDE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER PATIENT; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CASTRATION; CORRELATIONAL STUDY; DRUG EFFICACY; GROWTH RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNITY; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL ANALYSIS; METASTASIS; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; CLINICAL TRIALS, PHASE II AS TOPIC; COMPUTER SIMULATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NATIONAL CANCER INSTITUTE (U.S.); ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 79951826832     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1762     Document Type: Article

References (35)

1. American Cancer Society. Cancer Facts & Figures 2009. Atlanta: American Cancer Society; 2009. Available from:http://www.cancer.org/docroot/STT/ stt-0.asp
2. Petrylak D. Therapeutic options in androgen-independent prostate cancer: building on docetaxel. BJU Int 2005;96(Suppl 2):41-6. (Pubitemid 43041976)
3. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005;294:238-44. (Pubitemid 41043794)
4. Stein WD, Yang J, Bates SE, Fojo T. Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage. Oncologist 2008;13:1055-62.
5. Stein WD, Figg WD, Dahut W, Stein AD, Hoshen MB, Price D, et al. Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data. Oncologist 2008;13:1046-54.
6. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004a;351:125-35.
7. Hanks GE, Hanlon AL, Lee WR, Slivjak A, Schultheiss TE. Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior. Int J Radiat Oncol Biol Phys 1996;34:549-53. (Pubitemid 26069184)
8. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7. (Pubitemid 29211767)
9. Laufer P, Laufer M, Pound CR, Carducci MA, Eisenberger MA. Management of patients with rising prostate-specific antigen after radical prostatectomy. Urology 2000;55:309-15. (Pubitemid 30110573)
10. Egawa S, Arai Y, Tobisu K, Kuwao S, Kamoto T, Kakehi Y, Baba S. Use of pretreatment prostate-specific antigen doubling time to predict outcome after radical prostatectomy. Prostate Cancer Prostatic Dis 2000;3:269-74. (Pubitemid 32066537)
11. Stephenson AJ, Aprikian AG, Souhami L, Behlouli H, Jacobson AI, Begin LR, et al. Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. Urology 2002;59:652-6. (Pubitemid 34461971)
12. Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 2003;170:1872-6. (Pubitemid 37254948)
13. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 2004b;172:S42-6; discussion S46-7.
14. Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 2001;7:1888-93. (Pubitemid 32994822)
15. Figg WD, Liu Y, Arlen P, Gulley J, Steinberg SM, Liewehr DJ, et al. A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. J Urol 2005;173:790-6. (Pubitemid 40239343)
16. Figg WD, Arlen P, Gulley J, Fernandez P, Noone M, Fedenko K, et al. A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Semin Oncol 2001;28:62-6. (Pubitemid 32947554)
17. Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004;22:2532-9. (Pubitemid 41103740)
18. Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, et al. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:2070-6.
19. Arlen PM, Skarupa L, Pazdur M, Seetharam M, Tsang KY, Grosenbach DW, et al. Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol 2007;178:1515-20. (Pubitemid 47368382)
20. Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 2010;59:663-74.
21. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, et al. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:1099-105.
22. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461-7. Erratum in: J Clin Oncol 2007;25:1154. J Clin Oncol 2000;18:2644.
23. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148-59.
24. Laird AK. Dynamics of tumor growth. Br J Cancer 1964;13:490-502.
25. Schlom J, Arlen PM, Gulley JL. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 2007;13:3776-82. (Pubitemid 47037581)
26. Gulley JL, Madan RA, Arlen PM. Enhancing efficacy of therapeutic vaccinations by combination with other modalities. Vaccine 2007;25S:B86-B89.
27. Small E, Schellhammer P, Higano C, Redfern CH, Nemunaitis JJ, Valone FH, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24:3089-94. (Pubitemid 46638945)
28. Schellhammer P, Higano C, Berger E, Shore N, Small E, Penson D, et al. A randomized, double-blind, placebo-controlled, multi-center, phase III trial of sipuleucel-T in men with metastatic, androgen independent prostatic adenocarcinoma (AIPC). AUA Annual Meeting, 2009 [cited April 2010]. Available from:http://www.aua2009.org/program/lbsciforum.asp.
29. Rixe O, Fojo T. Is cell death a critical end point for anticancer therapies or is cytostasis sufficient? Clin Cancer Res 2007;13:7280-7.
30. Fojo AT, Stein WD, Wilkerson J, Bates SE. Kinetic analysis of breast tumor decay and growth following ixabepilone plus capecitabine (IXA + CAP) versus capecitabine alone (CAP) to discern whether the superiority of the combination is a result of slower growth, enhanced tumor cell kill, or both. J Clin Oncol 2010;28:15s(Suppl; abstr 1096).
31. Wilkerson J, Stein WD, Kim ST, Huang X, Motzer RJ, Fojo AT, et al. Validation of a kinetic analysis of renal cancer regression and growth following treatment with sunitinib and interferon-alfa (IFN-α): analysis of the pivotal randomized trial. J Clin Oncol 2010;28:15s(Suppl; abstr 4597).
32. Higano C, Saad F, Somer B, Curti D, Petrylak CG, Drake F, et al. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC) [abstract]. ASCO Genitourinary Cancers Symposium 2009;LBA150.
33. Salazar LG, Disis ML. Cancer vaccines: the role of tumor burden in tipping the scale toward vaccine efficacy. J Clin Oncol 2005;23:7397-8. (Pubitemid 46291799)
34. Madan RA, Mohebtash M, Schlom J, Gulley JL. Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design. Expert Opin Biol Ther 2010;10:19-28.
35. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003;21:1232-7. (Pubitemid 46606398)